Our attorneys represented Switzerland-based pharmaceutical, biotech and specialty ingredients supplier Lonza in connection with its strategic acquisition of California-based InterHealth Nutraceuticals Inc., a portfolio company of Kainos Capital. The deal was valued up to US $300 million.
Lonza is one of the world’s leading and most-trusted suppliers to the life sciences industry, and InterHealth’s more than 15 branded ingredients, including its cornerstone ingredient, UC-II, which is revolutionizing the joint-health segment, are expected to complement its existing nutritional portfolio in the area of sports nutrition, weight management, immune health and pet health. The acquisition will also expand Lonza’s offerings into new areas such as cognitive and diabetic health.
“With this acquisition Lonza is taking a further step along our strategic path as a high-value supplier to the healthcare continuum,” Lonza CEO Richard Ridinger said. “We see significant positive synergies from this combination.”